Jonathan J Darrow

@JonathanDarrow

, policy, and the 's perspective. Business professor, attorney, innovation scholar, Medical School faculty.

Vrijeme pridruživanja: ožujak 2019.

Tweetovi

Blokirali ste korisnika/cu @JonathanDarrow

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @JonathanDarrow

  1. says tazemetostat (Tazverik), for epithelioid sarcoma (), had no beneficial effect for 85% of patients; "complete response" (CR) rate: 1.6% (1 of 62); relevance of CR to survival not discussed. No randomized control grp. 1 trial.

    Poništi
  2. 3. velj

    New policy on Priority ANDAs (under previous policy "roughly half of all ANDA submissions were designated as priority," said FDA)

    Poništi
  3. 30. sij
    Poništi
  4. 23. sij
    Poništi
  5. proslijedio/la je Tweet

    US has been on an accelerating "reversal of fortunes" public health trajectory since the 1980s

    Prikaži ovu nit
    Poništi
  6. 5. sij

    When discussing high spending, the contribution of volume (vs price) is often downplayed. Our study, just published, found increased volume contributed 90% of public sector spending growth on oncology drugs in Chile.

    Poništi
  7. 2. sij

    A 4-minute history of (pharmacy benefit managers) from NPR/Kaiser:

    Poništi
  8. 12. pro 2019.

    Acetominophen/paracetamol (Tylenol) kills ~150 in US per year; 55,000+/year hospitalized. Generally from liver toxicity / inadvertent overdose.

    Poništi
  9. 5. pro 2019.

    2nd trastuzumab (Herceptin) (Mylan) launched in US. No price info yet, but Mylan's pegfilgrastim (Fulphila/Neulasta) launched in 2018 at a 33% discount:

    Poništi
  10. 1. pro 2019.

    Can drug efficacy be so tiny that the excipient (inactive ingredient) is responsible for a substantial portion of perceived benefit? Some evidence suggests this may be the case for certain gold-containing arthritis medicines:

    Poništi
  11. 1. pro 2019.

    Higher prices to come? How is it that sellers from some countries (eg ) can sell *& ship* a product for less than the cost of US shipping alone? Part of the answer: a postal treaty that will be revised in July after a threatened US withdrawal:

    Poništi
  12. 13. stu 2019.

    CDC releases 2019 resistance report: 35k US deaths, 1/3 of which are from C dif.....and the major cause of C dif?? --> The use of (p39 of the CDC report)

    Poništi
  13. 13. stu 2019.

    Dear : Your may cost you $1,500 or $180,000 (a factor difference of >100)...and we won't tell you which until after you have had the procedure (PS: no refunds or returns allowed). Please sign to indicate your ...

    Poništi
  14. 31. lis 2019.

    New TB (just 50% effective) for adults already infected with begs the Q: Why not expand use of time-tested (~$3) BCG vaccine (used in 180 countries, and 70% effective (CDC est.)? FDA approved BCG, but it is not recommended in US.

    Poništi
  15. 23. lis 2019.

    How effective is Trikafta in treating ? --> reports the key figure is a 10% to 13.8% improvement in ppFEV (lung capacity measurement obtained by blowing into a hollow tube). Cost: $311,000/yr

    Poništi
  16. 21. lis 2019.

    More priority review vouchers should mean lower price per voucher (supply goes up --> price comes down (ceteris paribus)). This is in fact what we see:

    Poništi
  17. 9. lis 2019.

    For a terrific (and classic) book examining the history of the business of , see: The Social Transformation of American Medicine, by Paul Starr,

    Poništi
  18. 9. lis 2019.

    California "physician lobbying group" opposed state efforts to facilitate access to drugs. Not against drugs per se, ...but in their view patients should first pay the prescriber for advice, whether the patient wants it or not.

    Poništi
  19. 7. lis 2019.

    No such thing as an "international patent"? ARIPO comes close for 18 countries in Africa: Uganda says no will issue on products until 2033 (a permitted exclusion under a council decision).

    Poništi
  20. 3. lis 2019.

    New paper from + Acri finds "generally no relationship" between a 's therapeutic category and "effective life" (w/ some caveats). The paper also offers a lesson in why magnitude is more important than statistical significance.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·